InspireMD Plans FDA Submission by Year-End Following TCAR Approval
InspireMD (NSPR) has identified the third quarter as a strategic turning point for the company, driven largely by the recent approval of its Transcatheter Closure of the Aortic Regurgitation (TCAR) procedure. Management estimates that this technology could add approximately 40,000 annual procedures to their clinical reach. To fund the next phase of growth and support full commercialization efforts, the company has announced a proposed underwritten equity public offering. This capital raise is intended to provide the necessary liquidity to transition from regulatory milestones to active market expansion.
Tickers: $NSPR
Topics: capital raising commercialization earnings report equity offering